156 related articles for article (PubMed ID: 31524211)
1. Bifunctional liposomes reduce the chemotherapy resistance of doxorubicin induced by reactive oxygen species.
Xu L; Zhang Z; Ding Y; Wang L; Cheng Y; Meng L; Wu J; Yuan A; Hu Y; Zhu Y
Biomater Sci; 2019 Nov; 7(11):4782-4789. PubMed ID: 31524211
[TBL] [Abstract][Full Text] [Related]
2. Anti-tumor effect via passive anti-angiogenesis of PEGylated liposomes encapsulating doxorubicin in drug resistant tumors.
Kibria G; Hatakeyama H; Sato Y; Harashima H
Int J Pharm; 2016 Jul; 509(1-2):178-187. PubMed ID: 27234700
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Radioresistance in Tumor Therapy by Alleviating Hypoxia and Using the HIF-1 Inhibitor.
Zhou X; Liu H; Zheng Y; Han Y; Wang T; Zhang H; Sun Q; Li Z
ACS Appl Mater Interfaces; 2020 Jan; 12(4):4231-4240. PubMed ID: 31912727
[TBL] [Abstract][Full Text] [Related]
4. Hypoxic tumor therapy by hemoglobin-mediated drug delivery and reversal of hypoxia-induced chemoresistance.
Yang J; Li W; Luo L; Jiang M; Zhu C; Qin B; Yin H; Yuan X; Yin X; Zhang J; Luo Z; Du Y; You J
Biomaterials; 2018 Nov; 182():145-156. PubMed ID: 30121013
[TBL] [Abstract][Full Text] [Related]
5. Combined mTOR inhibitor rapamycin and doxorubicin-loaded cyclic octapeptide modified liposomes for targeting integrin α3 in triple-negative breast cancer.
Dai W; Yang F; Ma L; Fan Y; He B; He Q; Wang X; Zhang H; Zhang Q
Biomaterials; 2014 Jul; 35(20):5347-5358. PubMed ID: 24726747
[TBL] [Abstract][Full Text] [Related]
6. Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.
Gao M; Xu Y; Qiu L
J Liposome Res; 2017 Jun; 27(2):151-160. PubMed ID: 27250110
[TBL] [Abstract][Full Text] [Related]
7. Co-Delivery of Metformin Enhances the Antimultidrug Resistant Tumor Effect of Doxorubicin by Improving Hypoxic Tumor Microenvironment.
Li Y; Luo J; Lin MT; Zhi P; Guo WW; Han M; You J; Gao JQ
Mol Pharm; 2019 Jul; 16(7):2966-2979. PubMed ID: 31095914
[TBL] [Abstract][Full Text] [Related]
8. Targeting acute hypoxic cancer cells by doxorubicin-immunoliposomes directed by monoclonal antibodies specific to RON receptor tyrosine kinase.
Guin S; Ma Q; Padhye S; Zhou YQ; Yao HP; Wang MH
Cancer Chemother Pharmacol; 2011 May; 67(5):1073-83. PubMed ID: 20658288
[TBL] [Abstract][Full Text] [Related]
9. Tumor oxygenation nanoliposome synergistic hypoxia-inducible-factor-1 inhibitor enhanced Iodine-125 seed brachytherapy for esophageal cancer.
Yao X; Lu S; Feng C; Suo R; Li H; Zhang Y; Chen Q; Lu J; Wu B; Guo J
Biomaterials; 2022 Oct; 289():121801. PubMed ID: 36137416
[TBL] [Abstract][Full Text] [Related]
10. Star-shape copolymer of lysine-linked di-tocopherol polyethylene glycol 2000 succinate for doxorubicin delivery with reversal of multidrug resistance.
Wang J; Sun J; Chen Q; Gao Y; Li L; Li H; Leng D; Wang Y; Sun Y; Jing Y; Wang S; He Z
Biomaterials; 2012 Oct; 33(28):6877-88. PubMed ID: 22770799
[TBL] [Abstract][Full Text] [Related]
11. Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis.
Yu C; Zhou M; Zhang X; Wei W; Chen X; Zhang X
Nanoscale; 2015 Mar; 7(13):5683-90. PubMed ID: 25740312
[TBL] [Abstract][Full Text] [Related]
12. In vitro and in vivo effect of hyaluronic acid modified, doxorubicin and gallic acid co-delivered lipid-polymeric hybrid nano-system for leukemia therapy.
Shao Y; Luo W; Guo Q; Li X; Zhang Q; Li J
Drug Des Devel Ther; 2019; 13():2043-2055. PubMed ID: 31388296
[No Abstract] [Full Text] [Related]
13. Glucose modulation induces reactive oxygen species and increases P-glycoprotein-mediated multidrug resistance to chemotherapeutics.
Seebacher NA; Richardson DR; Jansson PJ
Br J Pharmacol; 2015 May; 172(10):2557-72. PubMed ID: 25586174
[TBL] [Abstract][Full Text] [Related]
14. Improvement in the drug delivery and anti-tumor efficacy of PEGylated liposomal doxorubicin by targeting RNA aptamers in mice bearing breast tumor model.
Moosavian SA; Abnous K; Badiee A; Jaafari MR
Colloids Surf B Biointerfaces; 2016 Mar; 139():228-36. PubMed ID: 26722819
[TBL] [Abstract][Full Text] [Related]
15. Azoreductase-Responsive Metal-Organic Framework-Based Nanodrug for Enhanced Cancer Therapy via Breaking Hypoxia-induced Chemoresistance.
Huang C; Tan W; Zheng J; Zhu C; Huo J; Yang R
ACS Appl Mater Interfaces; 2019 Jul; 11(29):25740-25749. PubMed ID: 31251022
[TBL] [Abstract][Full Text] [Related]
16. Selection and optimization of nano-formulation of P-glycoprotein inhibitor for reversal of doxorubicin resistance in COLO205 cells.
Dash TK; Konkimalla VSB
J Pharm Pharmacol; 2017 Jul; 69(7):834-843. PubMed ID: 28397291
[TBL] [Abstract][Full Text] [Related]
17. Doxorubicin-loaded nanocarriers: A comparative study of liposome and nanostructured lipid carrier as alternatives for cancer therapy.
Fernandes RS; Silva JO; Monteiro LOF; Leite EA; Cassali GD; Rubello D; Cardoso VN; Ferreira LAM; Oliveira MC; de Barros ALB
Biomed Pharmacother; 2016 Dec; 84():252-257. PubMed ID: 27664949
[TBL] [Abstract][Full Text] [Related]
18. GE11-Directed Functional Polymersomal Doxorubicin as an Advanced Alternative to Clinical Liposomal Formulation for Ovarian Cancer Treatment.
Zou Y; Xia Y; Meng F; Zhang J; Zhong Z
Mol Pharm; 2018 Sep; 15(9):3664-3671. PubMed ID: 29570299
[TBL] [Abstract][Full Text] [Related]
19. Tumor Oxygenation and Hypoxia Inducible Factor-1 Functional Inhibition via a Reactive Oxygen Species Responsive Nanoplatform for Enhancing Radiation Therapy and Abscopal Effects.
Meng L; Cheng Y; Tong X; Gan S; Ding Y; Zhang Y; Wang C; Xu L; Zhu Y; Wu J; Hu Y; Yuan A
ACS Nano; 2018 Aug; 12(8):8308-8322. PubMed ID: 30102510
[TBL] [Abstract][Full Text] [Related]
20. VCPA, a novel synthetic derivative of α-tocopheryl succinate, sensitizes human gastric cancer to doxorubicin-induced apoptosis via ROS-dependent mitochondrial dysfunction.
Wu H; Liu S; Gong J; Liu J; Zhang Q; Leng X; Zhang N; Li Y
Cancer Lett; 2017 May; 393():22-32. PubMed ID: 28216375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
